Claudin 18.2 antibodies, antigen binding fragments and antibody drug conjugates thereof and methods of use in cancer therapy
Anti-CLDN18.2 antibodies and ADCs with specific CDR sequences address the limitations of existing therapies by enhancing binding affinity and efficacy, effectively targeting and killing CLDN18.2-positive cancer cells, particularly in gastric, pancreatic, and lung tumors.
WO2026115454A2PCT designated stage Publication Date: 2026-06-04ASTRAZENECA AB
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- ASTRAZENECA AB
- Filing Date
- 2025-11-26
- Publication Date
- 2026-06-04
Smart Images
Figure IB2025062094_04062026_PF_FP_ABST
Abstract
Provided are antibodies, antigen binding fragments, and immunoconjugates thereof that specifically bind to claudin 18.2 expressing cells, along with pharmaceutical compositions and kits comprising the antibodies, antigen binding fragments, and / or immunoconjugates. Methods of use of the antibodies, antigen binding fragments, and immunoconjugates in the treatment of claudin 18.2 expressing tumor cells is also provided.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Recombinant immunoglobin preparations
US4816567A
Single polypeptide chain binding molecules
US4946778A
Humanized immunoglobulins
US5585089A
Low pH hydrophobic interaction chromatography for antibody purification
US5641870A
Polynucleotides encoding improved humanized immunoglobulins
US5693761A